Much of his practice focuses on legal and technical matters associated with potential human and environmental exposures to toxic substances. Mr. Quill has extensive experience in the regulatory and political processes concerning dioxin and in assessing the toxicity and environmental fate of dioxins, PCBs and other chemical substances. Prior to his legal career, Mr. Quill held research positions specializing in molecular and developmental genetics, immunochemistry and tumor immunology. I have worked quite a bit with the chemical industry on the endocrine disruption issue, so I can share with you the general industry views and positions on a number of issues in this area. There is not a lot of agreement on some of these issues even within the chemical industry.
Endocrine disruption is a maze.
We have to take a step back and view the maze from the top to determine where we want to go. Part of this is involves trying to determine exactly what we need to research. The hypothesis that needs to be tested is whether low level chemical exposures cause adverse endocrine-related effects on humans or wildlife. That is what our research should revolve around to a large extent. Some people will say that we have the evidence that there are endocrine-related adverse effects in wildlife, and we're certain it is happening in humans.